Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study.

Department of Neurological Sciences, Federico II University, Naples, Italy.
Neurology (Impact Factor: 8.3). 05/2006; 66(8):1207-10. DOI: 10.1212/01.wnl.0000208402.10512.4a
Source: PubMed

ABSTRACT Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset between age 10 and 22 years, cerebellar atrophy, peripheral neuropathy, oculomotor apraxia (OMA), and elevated serum alpha-fetoprotein (AFP) levels. Recessive mutations in SETX have been described in AOA2 patients.
To describe the clinical features of AOA2 and to identify the SETX mutations in 10 patients from four Italian families.
The patients underwent clinical examination, routine laboratory tests, nerve conduction studies, sural nerve biopsy, and brain MRI. All were screened for SETX mutations.
All the patients had cerebellar features, including limb and truncal ataxia, and slurred speech. OMA was observed in two patients, extrapyramidal symptoms in two, and mental impairment in three. High serum AFP levels, motor and sensory axonal neuropathy, and marked cerebellar atrophy on MRI were detected in all the patients who underwent these examinations. Sural nerve biopsy revealed a severe depletion of large myelinated fibers in one patient, and both large and small myelinated fibers in another. Postmortem findings are also reported in one of the patients. Four different homozygous SETX mutations were found (a large-scale deletion, a missense change, a single-base deletion, and a splice-site mutation).
The clinical phenotype of oculomotor apraxia type 2 is fairly homogeneous, showing only subtle intrafamilial variability. OMA is an inconstant finding. The identification of new mutations expands the array of SETX variants, and the finding of a missense change outside the helicase domain suggests the existence of at least one more functional region in the N-terminus of senataxin.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ataxia oculomotor apraxia type 2 (AOA2) is a rare autosomal recessive disorder characterized by cerebellar atrophy, peripheral neuropathy, loss of Purkinje cells and elevated α-fetoprotein. AOA2 is caused by mutations in the SETX gene that codes for the high molecular weight protein senataxin. Mutations in this gene also cause dominant neurodegenerative disorders. Similar to that observed for other autosomal recessive ataxias, this protein protects the integrity of the genome against oxidative and other forms of DNA damage to reduce the risk of neurodegeneration. Senataxin functions in transcription termination and RNA splicing and it has been shown to resolve RNA/DNA hybrids (R-loops) that arise at transcription pause sites or when transcription is blocked. Recent data suggest that this protein functions at the interface between transcription and DNA replication to minimise the risk of collision and maintain genome stability. Our recent data using SETX gene-disrupted mice revealed that male mice were defective in spermatogenesis and were infertile. DNA double strand-breaks persisted throughout meiosis and crossing-over failed in SETX mutant mice. These changes can be explained by the accumulation of R-loops, which interfere with Holiday junctions and crossing-over. We also showed that senataxin was localized to the XY body in pachytene cells and was involved in transcriptional silencing of these chromosomes. While the defect in meiotic recombination was striking in these animals, there was no evidence of neurodegeneration as observed in AOA2 patients. We discuss here potentially different roles for senataxin in proliferating and post-mitotic cells.
    Rare diseases (Austin, Tex.). 01/2013; 1:e25230.
  • [Show abstract] [Hide abstract]
    ABSTRACT: R loops are three-stranded nucleic acid structures that comprise nascent RNA hybridized with the DNA template, leaving the nontemplate DNA single-stranded. R loops form naturally during transcription even though their persistent formation can be a risky outcome with deleterious effects on genome integrity. On the other hand, over the last few years, an increasingly strong case has been built for R loops as potential regulators of gene expression. Therefore, understanding their function and regulation under these opposite situations is essential to fully characterize the mechanisms that control genome integrity and gene expression. Here we review recent findings about these interesting structures that highlight their opposite roles in cellular fitness.
    Genes & Development 07/2014; 28(13):1384-1396. · 12.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Ataxia telangiectasia (AT) is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, hypersensitivity to ionizing radiation, and predisposition to malignancy. AT is caused by mutations in ataxia telangiectasia mutated (ATM) gene encoding ATM, a protein kinase responsible of DNA damage response and cell cycle control. Patients with the classical form of AT survive until the second-third decade of life; the major cause of death are lung disease due to recurrent sinopulmonary infections and cancer (T-cell leukemia and lymphoma). Treatment of primary manifestations of AT has been so far unsuccessful. Early and continued physical therapy, IVIG replacement and antibiotic treatments reduce number and severity of infections prolonging the lifespan of patients. Recently, dopaminergic drugs were shown to improve the control of movement disorders and steroids were demonstrated to dramatically reduce the neurological features.Areas covered: Clinical and molecular aspects of AT as well as pathogenesis, differential diagnosis and current treatments are summarized.Expert opinion: Efficacy of steroids in improving ataxia of AT patients is proven. To avoid the side effects of long-term administration of steroids, encapsulation of the drug into erythrocytes followed by slow release appears promising. Moreover, extrapyramidal symptoms may be ameliorated by dopaminergic drugs. Long-term, placebo-controlled studies are needed for these treatments.
    Expert Opinion on Orphan Drugs. 08/2014;


Available from
Nov 5, 2014